Lupin is currently the top gainer on the BSE, opening 1% higher at Rs.890 but soon rose to an intraday high at Rs.972.50, up 10%, on the back of an 8-times surge in volumes.

The stock price rose after it announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility. The US drug regulator had inspected the facility in September 2021.

The company said that the Goa site has a very important place in the US market with the number of affordable, quality medicines we supply, and it expects new products flowing out of the site again.